Exelixis (EXEL) Stock Price, News & Analysis

Company Overview

Exelixis, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer. The company’s research and development activities are centered primarily on targeted therapies and other treatments for solid tumors.

Exelixis’ principal product is cabozantinib, marketed in the United States as CABOMETYX tablets for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. The company also markets COMETRIQ, a cabozantinib formulation approved in the United States for progressive or metastatic medullary thyroid cancer.

Exelixis was founded in 1994 and is headquartered in Alameda, California. Its medicines are marketed internationally through a combination of direct commercial activities and collaborations, including partnerships that support the availability of cabozantinib in markets outside the United States. The company continues to advance a pipeline of oncology candidates, including investigational therapies designed to address additional tumor types and treatment settings.

Michael M. Morrissey has served as Exelixis’ president and chief executive officer since 2010. The company’s common stock trades on the Nasdaq under the symbol EXEL.

Key Stats

• Today's Range: $58.59 to $60.00
• 50-Day Range: $50.38 to $59.86
• 52-Week Range: $33.76 to $61.66
• Volume: 2.62 million shs
• Average Volume: 2.28 million shs
• Market Capitalization: $14.75 billion
• P/E Ratio: 18.71
• Dividend Yield: N/A
• Price Target: $50.79
• Consensus Rating: Hold

Exelixis Stock Analysis - MarketRank™

Exelixis scored higher than 47% of companies evaluated by MarketBeat, and ranked 594th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Exelixis has received a consensus rating of Hold. The company's average rating score is 2.35, and is based on 1 strong buy rating, 6 buy ratings, 12 hold ratings, and 1 sell rating.

Downside Risk

Exelixis has a consensus price target of $50.79, representing about 14.7% downside from its current price of $59.51.

Amount of Analyst Coverage

Exelixis has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 16.30%

Earnings Growth

Earnings for Exelixis are expected to grow by 16.30% in the coming year, from $3.19 to $3.71 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Exelixis is 18.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.

Price to Earnings Ratio vs. Sector

The P/E ratio of Exelixis is 18.71, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.97.

Price to Earnings Growth Ratio

Exelixis has a PEG Ratio of 1.78. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Exelixis has a P/B Ratio of 7.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.68% of the float of Exelixis has been sold short.

Short Interest Ratio / Days to Cover

Exelixis has a short interest ratio ("days to cover") of 12.65, which indicates bearish sentiment.

Change versus previous month

Short interest in Exelixis has recently increased by 6.75%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exelixis does not currently pay a dividend.

Dividend Growth

Exelixis does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.34

News Sentiment

Exelixis has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 24 news articles for Exelixis this week, compared to 9 articles on an average week.

Search Interest

18 people have searched for EXEL on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.

MarketBeat Follows

12 people have added Exelixis to their MarketBeat watchlist in the last 30 days. This is an increase of 140% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Exelixis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $526,512.00 in company stock.

Percentage Held by Insiders

2.60% of the stock of Exelixis is held by insiders.

Percentage Held by Institutions

85.27% of the stock of Exelixis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EXEL
• CIK: 939767
• Web: www.exelixis.com
• Phone: (650) 837-7000
• Fax: 650-837-8300
• Employees: 1,077
• Year Founded: 1994

Price Target and Rating

• Average Price Target for Exelixis: $50.79
• High Price Target: $56.00
• Low Price Target: $36.00
• Potential Upside/Downside: -14.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.35
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.18
• Trailing P/E Ratio: 18.71
• Forward P/E Ratio: 18.66
• P/E Growth: 1.68
• Net Income: $782.57 million
• Net Margins: 35.33%
• Pretax Margin: 42.51%
• Return on Equity: 42.17%
• Return on Assets: 31.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.46
• Quick Ratio: 3.38

Sales & Book Value

• Annual Sales: $2.32 billion
• Price / Sales: 6.36
• Cash Flow: $3.01 per share
• Price / Cash Flow: 19.76
• Book Value: $8.06 per share
• Price / Book: 7.38

Miscellaneous

• Outstanding Shares: 247,780,000
• Free Float: 241,340,000
• Market Cap: $14.75 billion
• Optionable: Optionable
• Beta: 0.47